Skip to main content

Table 3 Clinical features for the patients receiving carbapenems or other antibiotics on day 0

From: Epidemiology and prognosis of anti-infective therapy in the ICU setting during acute pancreatitis: a cohort study

 Missing dataCarbapenems n = 81Other AIT n = 278p value
Severity criteria at day 0
 SOFA score, median [IQR]4/95 [3–7]5 [3–7]NS
 Respiratory failure*, n (%)032 (40)103 (37)NS
 Cardiovascular failure*, n (%)039 (48)123 (44)NS
 Renal failure*, n (%)014 (17)53 (19)NS
 Septic shock, n (%)029 (36)81 (29)NS
 Acute respiratory distress syndrome, n (%)011 (14)26 (9)NS
Main reasons for anti-infective therapy at day 0
 Empirical therapy, n (%)067 (83)232 (83)NS
 Intra-abdominal infection, n (%)1/555 (69)155 (57)NS
 Pneumonia, n (%)2/67 (9)39 (14)NS
 Bacteraemia, n (%)2/36 (8)39 (14)NS
 Catheter-related infection, n (%)2/32 (3)7 (3)NS
 Urinary tract infection, n (%)2/49 (3)NS
 Skin and soft tissue infection, n (%)2/32 (1)NS
Most frequently prescribed anti-infective agents at day 0
 Beta-lactams, n (%)081 (100)191 (69)< 0.001
 Aminoglycosides, n (%)041 (51)79 (28)< 0.001
 Anti-Gram-positive agents, n (%)020 (30)30 (11)< 0.01
 Antifungal agents, n (%)020 (25)33 (12)< 0.01
 Azoles, n (%)018 (22)28 (10)< 0.01
 Echinocandins, n (%)01 (1)4 (1)NS
Duration of AIT, days, median [IQR]3/87 [3–15]4 [1–10]< 0.01
ICU length of stay, days, median [IQR]014 [4–27]8 [3–19]< 0.05
ICU readmission, n (%)0/15 (6)22 (8)NS
Hospital mortality, n (%)022 (27)71 (26)NS
Time to death, days, median [IQR]031 [7–43]3 [1–19]< 0.01
  1. NS non-significant
  2. *According to the definition of the SOFA score